

Reference : NPL/HO/CS/2024/231

Dated : November 14, 2024

**The Chairman**

Bangladesh Securities and Exchange Commission

E-6/C, Sher-E- Bangla Nogor

Agargaon, Dhaka.

**The Chief Regulatory Officer**

Dhaka Stock Exchange PLC.

DSE Tower

Plot # 46, Road #21

Nikunja-02, North airport road,

Dhaka-1229.

**The Chief Regulatory Officer**

Chittagong Stock Exchange PLC.

Eunus trade Centre (level-15)

52-53 Dilkusha C/A, Dhaka-1000


Subject: **Submission of Price Sensitive Information of Navana Pharmaceuticals PLC.**

**Dear Sir,**

We are pleased to submit herewith the **Price Sensitive Information** of Navana Pharmaceuticals PLC. which was took on 48<sup>th</sup> Board of Directors meeting held on November 14 , 2024 was started at 3.00 p.m. and ended at 5.00 p.m. in its head office: House # 99, Road # 04, Block # B, Banani, Dhaka-1213 for your kind information and record.

Thank you.

Regards,



**Lorens Shamol Mollick FCS**

Company Secretary

**Enclosed:** As stated above.



## NAVANA PHARMACEUTICALS PLC.

### Corporate Office:

House # 99, Road # 04, Block # B, Banani, Dhaka-1213

### PRICE SENSITIVE INFORMATION

This is for kind information to all valued shareholders of Navana Pharmaceuticals PLC. and stakeholders that the Board of Directors of the company in its 48<sup>th</sup> meeting held on 14<sup>th</sup> November, 2024 ended at 5.00 p.m. has considered and approved, among others, the Un-audited Financial Statements for the first quarter (Q1) period ended on September 30, 2024 and took the following Price Sensitive Decision:-

#### **Comparative Statement on Un-audited Financial Statement for the first quarter (Q1) of financial year-2024-2025 period ended on September 30, 2024:**


Sl. No	Particulars	01.07.2024-30.09.2024	01.07.2023-30.09.2023
I	Earnings Per Share (EPS)	1.25	1.11
ii	Net Operating Cash Flow Per Share (NOCFPS)	2.00	1.19
		<b>As at 30.09.2024</b>	<b>As at 30.06.2024</b>
iii	Net Asset Value (NAV)	4,674,043,449	4,561,095,559
iv	Net Asset Value Per Share	43.51	42.46

#### **Notes:**

- ❖ **Reasons of significant deviation in earning per share (EPS) & Net Operating Cash Flow per Share (NOCFPS) between the quarterly periods:**
  - EPS: Increase in Sales Revenue and efficient usages of material resulted in increased gross profit for the reporting period resulted in the increment of Earnings per Share (EPS) by 12.6% as well.
  - NOCFPS: Net Operating Cash Flow per Share (NOCFPS) has increased to Tk. 2.00 from Tk. 1.19, due to cash received from the customers was higher than the cash payment to the vendors in the reporting period.
- ❖ In compliance with the Dhaka & Chittagong Stock Exchange (Listing) Regulation, 2015, the company is pleased to publish the Un-audited Financial Statement for the first quarter (Q1) period ended on September 30, 2024 in two widely circulated daily newspapers (one in Bengali and other one in English) and also in an online news portal. The detail of the published quarterly Financial Statements will be available in the website (**www.navanapharma.com**) of the company.

Dated: November 14, 2024

By order of the Board


**Lorens Shamol Mollick FCS**

Company Secretary